ArticleFrontiers in oncology2026
Comparative analysis of radiation therapy plans before and after biodegradable hydrogel (SpaceOAR) injection for reducing rectal toxicity in patients with prostate cancer undergoing carbon ion radiotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbon ion radiotherapy (CIRT) offers superior dose conformity and biological effectiveness, making it an effective modality for treating prostate cancer. However, dose escalation is limited by the anatomical proximity of the rectum. Although the SpaceOAR™ hydrogel spacer has demonstrated efficacy in photon-based radiotherapy by reducing rectal dose, its application in CIRT remains insufficiently studied. This study aimed to assess the impact of SpaceOAR on dose distribution and plan robustness in patients with prostate cancer receiving CIRT. Methods: Twenty-five patients with clinically localized prostate cancer who received SpaceOAR insertion between the prostate and rectum were included. Treatment plans were generated using the RayStation treatment planning system and compared across conventional, rectum-protection, and post-SpaceOAR insertion plans in terms of dosimetry, including dose-volume histograms (DVHs). Robustness evaluation assessed plan stability against patient setup uncertainties, and ProKnow scoring was used to evaluate treatment plan quality. Results: Compared with conventional CIRT and rectum-protection plans without SpaceOAR, plans with SpaceOAR insertion resulted in a substantial reduction in rectal radiation dose across all 25 patients (p < 0.001). SpaceOAR insertion also improved overall plan quality, as reflected in DVH metrics and ProKnow scores (p < 0.001). Robust evaluation confirmed that SpaceOAR enhanced the safety and reliability of the treatment plans. Conclusions: Integrating SpaceOAR into CIRT for prostate cancer appears to reduce rectal radiation exposure, improves plan robustness, and enables potential dose escalation to the target volume without compromising safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.